ReviewHaematologica2017
The emerging role of immune checkpoint inhibition in malignant lymphoma.
Review in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.Acta clinica Croatica · 2018Guideline
- Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.British journal of haematology · 2025Trial
- Single-cell insights into the role of T cells in B-cell malignancies.FEBS letters · 2025Review
- Trends and projections of Non-Hodgkin lymphoma burden (1990-2040): a global burden of disease 2021 analysis.BMC public health · 2025Article
- Article
- Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP).Medicina (Kaunas, Lithuania) · 2024Article
- The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma.Metabolites · 2023Review
- Article
- CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.The journal of pathology. Clinical research · 2022Article
- Increasing Role of Targeted Immunotherapies in the Treatment of AML.International journal of molecular sciences · 2022Review
- Identification ofFrontiers in genetics · 2022Article
- IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL.BMC cancer · 2021Article
- The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Cancer cell · 2021Review
- Immune-Checkpoint Inhibitors in B-Cell Lymphoma.Cancers · 2021Review
- PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.Bone marrow transplantation · 2021Article
- A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.Frontiers in immunology · 2021Review
- Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research.Frontiers in oncology · 2021Review
- Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.The oncologist · 2020Article
- Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.Cancer immunology, immunotherapy : CII · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evade elimination by the host immune system, tumor cells commonly exploit physiological immune checkpoint pathways, restraining efficient anti-tumor immune cell function. Growing understanding of the complex dialog between tumor cells and their microenvironment contributed to the development of immune checkpoint inhibitors. This innovative strategy has demonstrated paradigm-shifting clinical activity in various malignancies. Antibodies targeting programmed death 1 and cytotoxic T-lymphocyte-associated protein-4 are also being investigated in lymphoid malignancies with varying levels of activity and a favorable toxicity profile. To date, evaluated only in the setting of relapsed or refractory disease, anti-programmed death 1 antibodies such as nivolumab and pembrolizumab show encouraging response rates particularly in classical Hodgkin lymphoma but also in follicular lymphoma and diffuse-large B-cell lymphoma. As the first immune checkpoint inhibitor in lymphoma, nivolumab was approved for the treatment of relapsed or refractory classical Hodgkin lymphoma by the Food and Drug Administration in May 2016. In this review, we assess the role of the pathways involved and potential rationale of checkpoint inhibition in various lymphoid malignancies. In addition to data from current clinical trials, immune-related side effects, potential limitations and future perspectives including promising combinatory approaches with immune checkpoint inhibition are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.